• Equillium Inc EQ.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of two analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -23 cents to -14 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Equillium Inc's reported EPS for the quarter was a loss of 16 cents​.

• The company reported a quarterly loss of $5.74 million.

• Equillium Inc shares had risen by 325.1% this quarter and gained 79.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Equillium Inc is $1.00, about 34% below its last closing price of $1.34

This summary was machine generated from LSEG data August 19 at 11:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)